Preserving Public Trust and Demanding Accountability (Introduction to Part II)
Document Type
Book Chapter
Publication Date
2015
Editor(s)
Holly Fernandez Lynch & I. Glenn Cohen
ISBN
9780231540070
Publisher
Columbia University Press
Language
en-US
Abstract
The President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) recently said that “there is one great problem that seriously challenges the ability of America’s research-based pharmaceutical companies to . . . research and develop new cures and treatments. In a word, it is trust” (Pricewaterhouse Coopers’ Health Research Institute 2006). This section includes four chapters that explore the role of the drug and device industries, in this time when public trust has eroded. In two chapters, Patrick O’Leary and Katrice Bridges Copeland address the strategies that the United States government uses to prosecute industry transgressions. Alla Digilova, Barbara Bierer, Mark Barnes, and Rebecca Li discuss trends toward transparency in clinical trial data, which end an industry monopoly on this information. Genevieve Pham-Kanter provides a novel empirical analysis, which shows how industry financial ties are related to the votes of U.S. Food and Drug Administration (FDA) advisory board members.
Recommended Citation
Christopher Robertson,
Preserving Public Trust and Demanding Accountability (Introduction to Part II)
,
in
FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies
109
(Holly Fernandez Lynch & I. Glenn Cohen ed.,
2015).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/1822
